WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Nutritional Strategies for the management and treatment of Non-Alcoholic Fatty Liver Disease

Alisha Shaikh[1], Fiza Khan[2], Tuba Hashmi[3], Guided by:- Dr. Vanita Saharan[4], Mamta Pandey[5], Ganesh Mahale[6]

Premlila Vithaldas Polytechnic, SNDT Women's University

ABSTRACT :

Non-alcoholic fatty liver disease (NAFLD) is a build-up of excessive fat in the liver that can lead to liver damage. It is a common among various populations, particularly those with certain risk factors which include obese individuals, sedentary individuals, people with high fat diet, individuals with metabolic syndrome and also in people with Type 2 Diabetes due to Insulin resistance which is a significant risk factor for NAFLD. With no approved pharmacological treatment currently available, lifestyle interventions, specifically dietary modifications, remain the essential element in the management of NAFLD, underscoring the need for targeted nutritional approaches. This review endeavours to consolidate and critically evaluate the current evidence base regarding impact of specific dietary approaches in reducing liver fat accumulation and improving hepatic of well-established dietary patterns, such as Mediterranean, low carbohydrate, and DASH diets as well as intermittent fasting in the management of NAFLD. This review also examines the role of individual nutrients including omega 3 fatty acids, fructose, and coffee, and liver health and also delineates the intricate relationship between diet, gut microbiota and hepatic function.

Keywords: Fatty liver, Dietary interventions, Lifestyle Modifications, DASH Diet, Mediterranean diet, Liver health.

INTRODUCTION:

Non-Alcoholic Fatty Liver Disease (NAFLD) is a most prevalent chronic liver disorder globally, affecting most of the population worldwide. It is characterized by a spectrum of liver damage ranges from benign steatosis to more advanced non-alcoholic steatohepatitis (NASH), which may further lead to fibrosis, cirrhosis, or hepatocellular carcinoma. The strong correlation between NAFLD and metabolic disorders, such as obesity and type 2 diabetes, it highlights the importance of lifestyle modifications in disease prevention and management. The global burden of NAFLD is considerable, with recent epidemiological data revealing a significant increase in cases among in both adult and paediatric population. In the absence of approved pharmacological treatments for NAFLD highlights the need for alternative approaches such as lifestyle modifications, particularly dietary interventions including the Mediterranean diet, low carbohydrate and ketogenic diet, intermittent fasting in improving liver health, reducing liver fat, enhancing insulin sensitivity and also improving metabolic outcomes. In the recent years, dietary patterns and nutritional interventions have been increasingly recognized as crucial component in the management of NAFLD.

For example, the Mediterranean diet has been shown to have beneficial effect in patients with NAFLD due to its high context of anti-oxidant and antiinflammatory rich foods.

Alternative dietary approaches, such as low carbohydrate and intermittent fasting regimens have demonstrated potential in improving lipid metabolism and reducing hepatic fat accumulation. Targeted nutritional strategies, including reduction of fructose intake and increase in the consumption of omega-3 fatty acid and utilizing the hepatoprotective properties of coffee and specific polyphenols, may play a role in mitigating NAFLD progression.

PATHOPHYSIOLOGY OF NAFLD

The pathogenesis of Non-alcoholic fatty liver disease (NAFLD) develops from an intricate interplay of metabolic dysregulation, hormonal imbalance, inflammatory responses that ultimately lead to the excessive fat accumulation in hepatocytes. The progression from steatosis to Non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis is characterized by a complex cascade of events. The multiple parallel hits hypothesis provides a framework for understanding this progression, emphasizing the synergistic contributions of insulin resistance, inflammatory responses, oxidative stress, and gut microbiome dysbiosis, ultimately resulting in hepatic injury and fibrosis.

1. **Fat Accumulation in the Liver:**

   Hepatic steatosis is characterized by an imbalance between fatty acid uptake, oxidation, synthesis, and export which leads to excessive lipid accumulation within hepatocytes, resulting in early liver damage. Key mechanisms include:

   a. Increased delivery of free fatty acids (FFAs) from adipose tissue due to enhanced lipolysis.

b. Enhanced de novo lipogenesis (DNL) in the liver, especially triggered by high carbohydrate and fructose intake.

c. Impaired export of triglyceride as very low-density lipoprotein (VLDL).

d. Reduced fatty acid oxidation due to mitochondrial dysfunction.

2. **Role of Insulin Resistance:**

Insulin resistance plays a crucial role in the development of NAFLD. In insulin resistant states:

a. The liver continues to produce glucose and enhanced lipogenesis despite high insulin levels.

b. Peripheral tissue (like adipose and muscle) fails to respond effectively to insulin leading to increased lipolysis and elevated FFAs in circulation.

3. **Role of Inflammation :** Damaged hepatocytes release signals that activates Kupffer cells, leading to the secretion of inflammatory cytokines like Tumour necrosis factor alpha, Interleukin-6 (IL-6) and Interleukin I β.

4. **Role of Oxidative Stress**: The accumulation of fat in the liver leads to increase in the mitochondrial β oxidation resulting to the formation of reactive oxygen species (ROS). ROS damages the cellular components including protein, lipid, and DNA which contributes to disease progression.

EVIDENCE BASED DIETARY PATTERNS:

Diet plays a crucial role in the prevention and management of Non Alcoholic Fatty Liver Disease (NAFLD), with the evidence supporting specific dietary patterns that focus on metabolic dysfunction, reduce hepatic fat, and improve liver related outcomes. Below is an overview of four major dietary strategies that have shown therapeutic effect in NAFLD, based in the recent clinical findings.

a) Mediterranean Diet (MedDiet)

The Mediterranean diet is rich in vegetables, whole grains, fruits, nuts, fish, olive oil, legumes, seeds. It is one of the most effective dietary patterns for the management of NAFLD. The diet which includes high fibre, antioxidants, and monosaturated fats contributes to the reduction in hepatic fat content an improved insulin sensitivity. Recent studies have consistently linked MedDiset adherence to improved liver health.

b) Low- Carbohydrate and Ketogenic Diets

Low – Carbohydrate diets (LCDs) which includes ketogenic diet reduce hepatic lipogenesis by improving insulin sensitivity and reducing liver triglyceride accumulation .Recent studies have shown that LCDs result in rapid improvements in liver fat content, and also independent of significant weight loss.

c) Intermittent Fasting

Intermittent Fasting promotes insulin sensitivity, which reduces oxidative stress, and boosts autophagy all are helpful in NAFLD management. Recent studies which includes the reviews of ASM journal and others showed reductions in hepatic steatosis and body weight.

Intermittent fasting, including time restricted feeding and alternate day fasting, is gaining attention for its effect on metabolic health and liver fat reduction.

d) Dietary Approaches to Stop Hypertension (DASH Diet)

DASH diet originally designs to manage blood pressure, diet emphasizes vegetables, fruit, whole grains, and lean proteins which minimizes sodium and saturated fats. Emerging reviews highlights that DASH antioxidant rich component's and reduced sodium intake may improve metabolic parameters such as blood pressure, insulin resistance, and lipid levels, factors closely linked to NAFLD progression.

ROLE OF SPECIFIC NUTRIENTS AND FOODS IN NAFLD

While overall dietary habits are essential in managing Non-Alcoholic Fatty Liver Disease (NAFLD), emerging evidence emphasizes the significance of individual nutrients and food items that influence hepatic fat metabolism, insulin action, inflammation, and fibrotic changes. Recent data (2023–2025) points toward the impactful roles of fructose- containing beverages, omega-3 fatty acids, and coffee in either worsening or ameliorating liver health.

Fructose and Sugar-Sweetened Beverages

A high intake of fructose, particularly from sugar-sweetened drinks, has consistently been associated with the development and progression of NAFLD. Unlike glucose, fructose metabolism is primarily hepatic and bypasses the key control steps of glycolysis, leading to unregulated de novo lipogenesis. This results in excess triglyceride deposition within hepatocytes.

Multiple reviews have indicated a strong correlation between elevated fructose intake and

increased hepatic fat content, independent of body mass index. Furthermore, fructose has been linked to higher serum aminotransferases (ALT and AST), increased oxidative stress, and compromised gut integrity—factors that collectively contribute to liver inflammation and fibrogenesis through the gut-liver axis.

Omega-3 Polyunsaturated Fatty Acids

Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have shown notable promise in NAFLD therapy due to their anti-inflammatory and lipid- lowering effects. These nutrients, commonly obtained from marine sources like salmon and mackerel, suppress hepatic lipogenesis by downregulating enzymes such as SREBP-1c, while simultaneously enhancing fatty acid oxidation.
Recent meta-analyses confirm that omega-3 supplementation results in significant reductions in liver fat, improvements in lipid profiles, and normalization of liver enzyme levels. These benefits are evident regardless of concurrent weight loss, suggesting a direct mechanistic effect on liver metabolism and insulin sensitivity.

Coffee Consumption

Coffee, widely consumed across all demographics, has drawn scientific interest for its hepatoprotective properties. It contains a range of bioactive compounds—including caffeine
and chlorogenic acid—that exhibit antioxidant, anti-fibrotic, and insulin-sensitizing actions. Current literature supports an inverse association between regular coffee consumption and liver fibrosis progression. Mechanistically, coffee appears to upregulate endogenous
antioxidant enzymes such a glutathione peroxidase and catalase, while suppressing pro- inflammatory cytokines. This is reflected in lower transaminase levels and improved liver stiffness metrics among habitual consumers.

NUTRACEUTICALS AND DIETARY SUPPLEMENTS IN NAFLD

Due to the multifactorial nature of NAFLD, the use of nutraceuticals and dietary supplements is being explored as adjunctive interventions. While lifestyle modifications remain the cornerstone of management, certain supplements offer targeted molecular benefits, including attenuation of hepatic steatosis, oxidative stress reduction, insulin sensitization, and anti- inflammatory effects.

Vitamin E

Vitamin E is a lipid-soluble antioxidant known for its role in neutralizing reactive oxygen species (ROS). Clinical studies have demonstrated its efficacy in non-diabetic individuals with biopsy- proven NASH, showing improvements in hepatic steatosis, lobular inflammation, and hepatocyte ballooning. Meta-analyses also support its role in reducing serum ALT and AST. Nonetheless, long-term usage warrants caution due to potential risks such as haemorrhagic stroke and prostate malignancy in some populations.

Vitamin D

Vitamin D deficiency is prevalent in NAFLD patients. Supplementation has been hypothesized to yield anti-fibrotic and metabolic benefits, particularly through modulation of insulin resistance and inflammatory pathways. Although some trials report mild improvements in hepatic biomarkers, the findings remain inconsistent and appear to be dose- and duration- dependent.

Probiotics and Prebiotics

Alterations in gut microbiota composition and permeability play a critical role in NAFLD progression. Probiotics (beneficial bacteria) and prebiotics (non-digestible fibres) work synergistically to restore gut microbial balance, strengthen intestinal barrier function, and reduce systemic endotoxemia.
Recent reviews highlight their potential in reducing hepatic inflammation and improving metabolic indices. These findings reinforce the therapeutic relevance of the gut-liver axis as a target for intervention.

Silymarin(MilkThistle Extract)

Silymarin, derived from Silybum marianum, possesses antioxidant, anti-inflammatory, and membrane-stabilizing properties. Randomized controlled trials suggest it can reduce serum liver enzymes and markers of oxidative stress, particularly in early-stage NAFLD. Its hepatoprotective effects are attributed to its ability to scavenge free radicals and enhance hepatocyte resilience.

Omega-3 Supplementation

Omega-3 supplements, particularly standardized EPA and DHA formulations, have demonstrated
consistent efficacy in reducing intrahepatic triglyceride accumulation. They offer a practical alternative for individuals unable to meet recommended intakes via diet alone, and are now[7]
considered a clinically relevant tool for NAFLD management.

Clinical Implications and Future Directions

Nonalcoholic Fatty Liver Disease (NAFLD) is increasingly recognized as a critical global health issue, given its rising prevalence and the absence of approved pharmacological treatments. Consequently, dietary and lifestyle interventions are the cornerstone of current management practices.

Key Dietary Approaches:

Mediterranean Diet: Rich in healthy fats (olive oil), fresh fruits, vegetables, whole grains, lean proteins, and moderate consumption of fish. This dietary pattern is widely recommended due to its anti- inflammatory and antioxidant effects.
Low-Carbohydrate Diets: These diets prioritize reducing overall carbohydrate intake, particularly refined sugars and processed carbohydrates, thereby improving metabolic parameters such as insulin resistance and reducing hepatic fat accumulation.
Intermittent Fasting: Incorporates regular cycles of fasting and eating, which can enhance metabolic flexibility, support weight loss, reduce hepatic steatosis, and mitigate inflammatory markers associated with NAFLD.
DASH Diet (Dietary Approaches to Stop Hypertension): This diet emphasizes reducing sodium intake, increasing potassium-rich foods, whole grains, lean proteins, and healthy fats. It can benefit individuals with NAFLD by simultaneously addressing cardiovascular risk factors commonly associated with the condition.

These dietary patterns collectively contribute to:

- Significant reduction in liver fat deposits.
- Improvement in insulin sensitivity and glycemic control.
- Reduction in systemic inflammation and oxidative stress.

Early and proactive dietary counseling by registered dietitians can significantly slow disease progression. Personalized dietary plans enhance long-term adherence by carefully considering:

Importance of Early Intervention

- Patient's personal dietary preferences.
- Cultural dietary traditions and practices.
- Concurrent medical conditions (comorbidities).
- Economic circumstances and resource availability.

Role of Patient Education and Follow-up:

Comprehensive patient education, motivational counselling, and systematic follow-up sessions have shown to markedly improve adherence and health outcomes. Studies published in respected journals and databases such as SpringerLink, ScienceDirect, and BioMed Central underline the critical role of consistent support in achieving sustained lifestyle modifications.

Emerging Research on Gut Health: Recent investigations into the gut-liver axis offer promising new strategies. Dietary interventions that include probiotics (beneficial live bacteria) and prebiotics (dietary fibers that support beneficial bacteria) can positively influence:

- Gut barrier integrity and permeability.
- Balance and diversity of gut microbiota.

Potential of Nutraceuticals and Functional Foods:

Nutraceuticals and functional foods are increasingly investigated as adjunctive treatments for NAFLD.

Popular nutraceuticals under study include:

- **Vitamin E:** Known for its antioxidant properties, showing potential benefits in reducing liver fat and inflammation.
- **Omega-3 Fatty Acids:** Exhibit anti-inflammatory effects, improving lipid profiles and hepatic steatosis.
- **Polyphenols:** Naturally occurring compounds in fruits, vegetables, and beverages like tea and coffee, noted for antioxidant and anti-inflammatory effects.

Further robust randomized controlled trials (RCTs) are urgently needed to conclusively determine their effectiveness, optimal dosing regimens, and long-term safety profiles. **Future of Personalized Nutrition:**
Advancements in precision nutrition—customizing dietary recommendations based on genomic, metabolic, and microbiome data—represent a significant leap forward.

Precision nutrition could enable clinicians to:

- Develop highly individualized dietary plans.
- Enhance effectiveness by aligning interventions precisely with an individual's biological responses.

- Minimize ineffective trial-and-error practices, thus optimizing patient outcomes and adherence.

Influence of Diet and Nutrition on NAFLD Progression

The development and progression of non-alcoholic fatty liver disease (NAFLD) are closely connected to nutritional factors and everyday dietary choices. Regular consumption of excessive calories, especially from diets high in saturated fats, trans fats, refined carbohydrates like sugars, and beverages containing high amounts of fructose, significantly contributes to liver fat accumulation. These dietary patterns trigger processes such as increased fat synthesis in the liver, impaired energy production in liver cells, and reduced effectiveness of insulin, collectively exacerbating NAFLD.

a. Benefits of Healthy Dietary Patterns

Conversely, adopting diets rich in healthier fats like mono- and polyunsaturated fatty acids, alongside complex carbohydrates and dietary fiber, has shown protective effects on liver health. Diets like the Mediterranean diet and the DASH (Dietary Approaches to Stop Hypertension) diet are excellent examples, as they have been associated with improved cholesterol levels, reduced inflammation throughout the body, and increased insulin sensitivity. Additionally, specific dietary components such as omega-3 fatty acids found in fish, and polyphenols present in fruits, vegetables, and teas, have demonstrated the potential to lower liver triglycerides and mitigate oxidative stress in liver cells.

b. Nutritional Strategies and Liver Fat Reduction

Implementing nutritional strategies, including controlled calorie intake and practices like intermittent fasting, has also proven beneficial. These approaches not only help achieve weight loss but also significantly decrease liver fat content independently of weight reduction alone. This indicates that the overall quality of the diet, beyond just calorie counting, plays an essential role in managing and potentially reversing NAFLD. Hence, conscious dietary choices are vital for individuals aiming to improve their liver health and manage the progression of NAFLD.

Population at risk for NAFLD

NAFLD is characterized as a multifactorial disorder intricately linked with metabolic comorbidities. The most prominent risk factors include obesity, insulin resistance, dyslipidaemia, type 2 diabetes melltius and hypertension. This conditions significantly influences NAFLD prevalence and severity. Epidemiologically, NAFLD affects approximately 25- 30% of the adult population globally, and even higher prevalence among individuals with obesity (up to 80%) and type 2 diabetes (50-60%). Genetic modifiers, pre-eminently the PNPLA31148M allelic variant, confer heightened vulnerability to steatotic liver disease and fibrotic evolution.

Additionally, lifestyle factors such as malnutrition, sedentary behaviour, and disrupted sleep patterns exacerbate disease risk. Notably, the incidence of paediatric NAFLD is escalating in concordance with rising childhood obesity rates, often precipitating accelerated liver injury trajectories.

Major factors include

1. Insulin Resistance & Type 2 Diabetes Mellitus

Insulin resistance (IR) is a central to NAFLD pathogenesis : adipose tissue dysfunction increases free fatty acids (FFA) and pro- inflammatory cytokines, driving liver fat accumulation and inflammation. Insulin promotes de novo lipogenesis in the liver, worsening fat accumulation. Over time, this can progress from simple steatosis to inflammation and fibrosis. Patients with Type 2 diabetes have particularly high NAFLD prevalence- ranging from approximately 30% to 70%, with obese diabetics reaching ~76% prevalence.

2. Obesity, Dyslipidaemia & Hypertension (Metabolic Syndrome)

- Obesity, especially the central fat, is the most consistent risk predictor ,with ~80-90% prevalence of NAFLD among obese individuals. Central obesity is particularly harmful because it is more metabolically active than subcutaneous fat. It releases free fatty acids and pro-inflammatory cytokines(e.g., IL-6) directly into the portal vein, which leads to liver fat accumulation and inflammation.
- Dyslipidaemia- elevated triglycerides, low HDL and LDL, is commonly associated with

NAFLD. It contributes to hepatic fat build-up dur to increased availability of circulating lipids. This altered lipid metabolism promotes lipid toxicity in liver cells, triggering oxidative stress, mitochondrial dysfunction, all of which can accelerate the progression of the liver disease.

- Hypertension is frequently comorbid and independently linked to NAFLD and liver

fibrosis risk; studies show that NAFLD itself may promote arterial stiffness and raise blood pressure, indicating a bidirectional relationship.

3. Age & Gender

Age: As people reach older age (e.g.;>45 years), they accumulate more visceral fat, lose liver volume and regenerative capacity, and become more susceptible to oxidative stress all raising NAFLD risk.

Gender: Men often have 2x the prevalence of NAFLD compared to women (pre- menopause) , likely due to hormonal protection in women. Post-menopause risk rises as estrogen hormone declines. Androgen imbalance in women (e.g.; PCOS) also elevates risk.

4. Family History & Genetics

First degree relatives of NAFLD patients have significantly elevaed risk, genetic mechanisms often co-act with metabolic triggers. The PNLA3(patatin like phospholipase domain containing protein 3) TM6SF2, and MBOAT7 have been associated with increased liver fat accumulation and fibrosis progression. These genetic polymorphisms affects lipid metabolism, fat storage and inflammatory responses within hepatocytes.

5. Diet & Lifestyle

Western style diets- rich in saturated fats, refined sugars (especially fructose), and processed foods - are key contributes to NAFLD. Fructose promotes de novo lipogenesis and impairs fatty acid oxidation. Sedentary behaviour, poor sleep quality, high screen exposure increase NAFLD risk by provoking insulin resistance and inflammation. Sleeping less than 5-6 hours daily raises NAFLD risk (HR~ 1.19TO 1.44). Smoking (active or passive) associates with higher odds of NAFLD and is implicated in greater fibrosis severity. Passive smoking similarly modestly increases risk.

Pharmacological Treatment

While lifestyle and dietary interventions are foundational in managing non alcoholic fatty liver disease (NAFLD), pharmacological therapy becomes essential in patients with non alcoholic steatohepatitis (NASH), particularly when accompanied by moderate to severe fibrosis.
Although no single drug has yet gained universal regulatory approval for NAFLD treatment (except Resmetirom recently for NASH with fibrosis), several agents have demonstrated significant therapeutic benefits and are under investigation.

1. **Insulin Sensitizers** : Pioglitazone, a peroxisome proliferator- activated receptor gamma (PPAR-GAMMA) agonist, improves hepatic steatosis, inflammation. It is particularly beneficial in NAFLD patients with type 2 diabetes or prediabetes. However, the concern remain regarding its long term safety profile, including potential weight gain and fluid retention.
2. **GLP-I Receptor Agonists** : Agents such as semaglutide and liraglutide have gained attention due to their dual effect on glycaemic control and weight loss. Recent data showed that semaglutide achieving NASH resolution without worsening fibrosis in 59% of participants.
3. **Antioxidants** : Vitamin E is on of the most studied agents for non diabetic patients with biopsy proven NASH. It exerts effects through reducing oxidative stress and lipid peroxidation. However, its long term safety particularly in males, due to a possible association with prostate cancer- remains under debate.
4. **SGLT-2 Inhibitors :** Although primarily used for diabetes and also cardiovascular protection, SGLT-2 inhibitors (e.g., empagliflozin) have demonstrated promise in reducing hepatic fat and improving insulin sensitivity and also lowering transaminase levels.
5. **Thyroid Hormone Receptor -beta Agonist :** Resmetirom (MGL-3196), a selective agonist became the first FDA approved medication for NASH with fibrosis (not cirrhosis) in 2024. It reduces liver fat, inflammation, and also fibrosis with favourable safety data.
6. Statins are safe in NAFLD and recommended for dyslipidaemia to reduce cardiovascular risk.
7. **Emerging Therapies Under Investigation :**
    a. FXR Agonist (e.g., Obeticholic Acid) : Show promise in reducing fibrosis but raise concerns regarding pruritus and lipid changes.
    b. PDAR Agonists (e.g., Lanifibranor) : Multi agonists targeting PPAR-α/δ/γ, currently in Phase 3 trials for comprehensive NASH treatment.
8. Dual/Triple Incretin Therapies (e.g., Tirzepatide) : Mimic GLP-I, GIP, and glucagon actions -showing hepatic and also metabolic benefits.

Conclusion

Non- Alcoholic Fatty Liver Disease(NAFLD) is one of the most prevalent chronic condition globally, closely associated with poor dietary patterns, obesity, sedentary lifestyles, and metabolic disorder. This review highlights the critical role of dietary interventions in both, prevention and therapeutic management of NAFLD. Among the various evidence based dietary strategies, the Mediterranean diet consistently demonstrates the most substantial benefits, including reductions in hepatic fat accumulation, improved insulin sensitivity and cardiovascular protection. Other dietary patterns- such as low- carbohydrate and ketogenic diets, the DASH diet, and intermittent fasting- also show promise in improving liver outcomes and metabolic markers. Specific food components have also been implicated in NAFLD progression and resolution like excessive consumption of fructose and other sugar sweetened beverages is strongly linked to liver fat accumulation and fibrosis, whereas omega 3 fatty acids and coffee have been shown to exert protective effects. Moreover, the gut liver axis has gained increasing attention, with mounting evidence suggesting that dietary modulation of the gut microbiota can significantly influence NAFLD development and progression. Although pharmacological treatment such as GLP-1 receptor agonists, insulin sensitizers, vitamin e and other offer therapeutic potential. Future directions must emphasize large scale, long term clinical trials to evaluate combined dietary and pharmacological interventions. In conclusion, diet is not merely an adjunct but a fundamental component in the holistic management of NAFLD.

REFERERNCES

1. Alkhouri et al., Practical Lifestyle Management of NAFLD (Diabetes Spectrum, 2024)

2. Li et al., Dietary Inflammatory Index and NAFLD Risk (Frontiers in Nutrition, 2024)

3. Guo et al., Dietary Index for Gut Microbiota and NAFLD (BMC Gastroenterology, 2025)

4. Kirpich et al., Nutritional Strategies for Metabolic Liver Disease (Current Opinion in Endocrinology, 2024)

5. Macaluso et al., Nutraceutical Approaches in NAFLD (The Lancet Gastroenterology, 2023)

6. Sarin et al., Systematic Review on Functional Foods in NAFLD (PubMed, 2023)

7. Yang et al., Scoping Review on Nutrients and NAFLD (Nutrients, 2023)

8. Rahmani et al., Dietary Patterns Against NAFLD (BMC Nutrition, 2024)

9. Lee et al., Diet and Microbiota in NASH Reversal (ASM Microbiology Spectrum, 2023)

10. Wang et al., Comprehensive Review of Dietary Components in NAFLD (PMC, 2023)

11. Sanyal AJ., Future Perspectives in NAFLD Therapy: From Lifestyle to Targeted Therapies (Springer Nature, 2025.)

12. Mantzoros CS, Mastrogiannis D. Practical Lifestyle Management of Nonalcoholic Fatty Liver Disease for Busy Clinicians.American Diabetes Association (ADA), 2023. https://diabetesjournals.org

13. Polyzos SA, Katsiki N. Nutritional Strategies for Battling Obesity-Linked Liver Disease. https://link.springer.com

14. Neuschwander-Tetri BA, Abdelmalek MF. Dietary Patterns, Foods, and Nutrients to Ameliorate Non-Alcoholic Fatty Liver Disease: A Scoping Review. https://sciencedirect.com

15. Colognesi M, Di Pascoli M. Non-Alcoholic Fatty Liver Disease: Dietary and Nutraceutical Approaches. https://sciencedirect.com

16. Alferink LJ, Koehler EM. Which Dietary Patterns Fend Off Non-alcoholic Fatty Liver Disease? A Systematic Review of Observational and Interventional Studies [https://bmcmedicine.biomedcentral.com] (https://bmcmedicine.biomedcentral.com)

17. Park YM, Kim HN. Dietary Inflammatory Index and the Risks of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. https://frontiersin.org

18. Wang X, Zhang D Functional Foods and Dietary Supplements in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. https://tandfonline.com

19. Zhou D, Pan Q Healthy Diet Intervention Reverses the Progression of NASH Through Gut Microbiota Modulation. https://journals.asm.org

20. Heianza Y, Ma W The Association Between the Dietary Index for Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Insights from Gut–Liver Interactions. https://mdpi.com

21. Pharmacological Options in the Treatment of NAFLD (PMC 2023)

22. Epidemiology and Risk factors in NAFLD development MDPI Nutrients (2023)

23. Advancements in Understanding and Treating NAFLD (MDPI 2023)